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Objectives: To estimate health and social care resource use in treating individu-
als with Fragile X Syndrome (FXS) in Canada and the United Kingdom (UK). FXS is 
the most common inherited form of intellectual disability (ID) worldwide; however 
its impact on resource use is not well documented. MethOds: Delphi panels 
were formed to generate consensus-based estimates of resource use. Panelists 
from multiple disciplines were recruited (7 panelists in Canada, 6 in UK) and a 
questionnaire developed to obtain estimates from each panelist by 2 age groups, 2 
severity levels and 24 service types for each of 9 items from the Aberrant Behavior 
Checklist (ABC) a proxy completed instrument to rate maladaptive behaviors of 
individuals with ID. A factor weight was estimated to differentiate costs by gender 
and a self-declared confidence score (1 – 5) was reported for each ABC item. Mean 
total service counts and coefficients of variation (CV) were calculated to assess 
variance between panelists and between rounds. Initial results were reviewed 
with panelists in a facilitated group discussion after which the questionnaire was 
repeated. Final data were based on the second round of estimation. Results: 
Comprehensive resource data were collected for both countries. There was lower 
variance and higher confidence in both countries in round 2 compared to 1. 
Rounds 1 and 2 means (CV) for Canada were [6,723 (0.69) 8,575 (0.52)] and for 
UK were [6,953 (0.96) 6,023 (0.76)]. The average level of self-declared confidence 
increased from 2.6 to 3.3 in Canada and from 2.6 to 2.8 in the UK. cOnclusiOns: 
The study generated comprehensive resource use data for treating individuals 
with FXS in Canada and the UK. Credible and validated estimates were generated 
through group discussion and refinement of initial estimates. The resulting data 
will be important in performing economic evaluations of treatments for patients 
with FXS.
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Objectives: To gain an understanding of the impact of bariatric surgery on the 
current medical management of obese patients. MethOds: The EGB database is 
a 1/97 representative sample (around 600,000 individuals) of the national claims 
database covering the whole French population including outpatients and inpa-
tient care. Adult patients treated for the first time over the period 01/01/2007 to 
31/12/2009 by bariatric surgery were identified through related procedures and 
obesity ICD-10 codes. A cohort of patients was constituted with a 2-year follow-up 
before and after the index procedure date (T). Reimbursed medical consumption 
over this 4-year period was recorded and presence of co-morbidities was identified 
through ICD-10 codes, reimbursement of specific drugs or procedures. Results: 
A total of 350 patients meeting the selection criteria were identified in the data-
base with a mean age of 38.9 (+/- 11.3) years, 83.4% female and 69.7% had a BMI 
in the range 40-50. The distribution of patients according to bariatric procedure 
was gastric banding (62.6%), gastric by-pass (19.7%), sleeve gastrectomy (16.6%) 
and bilio-pancreatic diversion (1.1%). The annual per capita reimbursed health 
expenses evolved from 2.633€ (+/-3.124€ ) in Year (T-2), to 3.557€ (+/-3.380€ ) in Year 
(T-1), to 4.240€ (+/-3.840€ ) in Year (T+1) (excluding procedure cost) to 3.755€ (+/-
5.037€ ) in Year (T+2). In 39% of patients those costs decreased between T-2 and 
T+2, (> 5%) and the only two variables significantly explaining this decrease were 
the reduction of consumption for anti-Diabetes and/or anti-Hypertension drugs. 
Most items of medical consumption increased over the period pre and post proce-
dure but started to decrease in Year T+2. cOnclusiOns: The visits for preparing 
bariatric surgery were probably an opportunity for those patients to benefit from 
a general check-up which has generated extra short term medical consumption. 
Additional research with longer follow up could better capture the benefits of 
bariatric surgery on medical consumption.
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Objectives: To assess treatment cost and duration (months) of major cytoge-
netic response (MCyR) using ponatinib in patients intolerant or resistant to 2G 
TKI, compared to treating with only 2G TKIs, in patients with Ph+ leukemia, in 
Italy. MethOds: A 3-year Markov model with 1-year cycles simulated patients 
with Ph+ leukemia to estimate outcomes in those eligible for ponatinib therapy, 
defined as 1) 2G TKI-resistant, 2) 2G TKI-intolerant if imatinib is not clinically 
appropriate, or 3) with T315I mutation. Eligible patients received treatment 
sequences including 2G TKIs and ponatinib in the ponatinib arm and 2G TKI 
only in the comparator arm. Patients without MCyR by 12 months were switched 
to the next therapy line until TKI options were exhausted, then to best sup-
portive care. MCyR rates for 2G TKI or ponatinib were estimated from clinical 
trial data and expert opinion. Patients were assumed to accrue MCyR months 
until estimated treatment failure. Monthly treatment costs reflect approved 
EU dosing and list prices; cost of ponatinib was assumed equivalent to the 
US. Results: We estimated 184, 280, and 360 ponatinib-eligible patients in 
years 1-3, respectively. Treating ponatinib-eligible Ph+ leukemia patients with 
2G TKIs yielded a 3-year cost of € 58.51 million and a total of 2,536 months in 
MCyR, at an average cost of € 23,068/MCyR month. Using ponatinib in eligible 
patients cost € 79.54 million and provided 5,649 months in MCyR, at an average 
cost of € 14,079/MCyR month. cOnclusiOns: The treatment strategy includ-
primary care (range: 1.0%–9.4%) than in general hospitals (range: 5.8%–43.3%), and 
highest in specialist nephrology settings (range: 16.0%–97.6%). Also, prevalence rates 
increased with the CKD stage (1–2: 14.1%–27.9%; 3: 25.5%–91.1%; 4: 36.0%–85.5%; 5: 
97.6%). The cost of managing anaemia per patient per year varied across studies 
from £2,616 (2006–2007 Great British Pounds; GBP) to £3,740 (2006 GBP) in the UK, to 
€ 5,617 in France (cost year not reported). One study reported that the overall cost of 
managing anaemia was highest in patients with CKD Stage 3 compared with other 
stages (3: £4,162,056 vs. 4–5: £243,288; 2006–2007 GBP). Another study reported higher 
costs per patient per annum for individuals with lower haemoglobin (Hb) levels (Hb 
> 12 g/dL: € 2,418; Hb < 10 g/dL: € 13,005; cost year not reported). Among patients with 
CKD, those with anaemia were more likely to be hospitalised (61% vs. 50% of those 
without anaemia). cOnclusiOns: Anaemia is a highly prevalent condition in CKD 
across treatment settings in Europe, and the limited evidence available suggests it 
is associated with a substantial economic burden.
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Objectives: Peripheral neuropathic pain (PNP) implies a significant economic 
burden that results in major health care and indirect costs. The aim of the present 
analysis was modelling the association and predictive value of pain intensity on 
costs and resources utilization (health care and non-health resources) in patients 
with chronic PNP treated in routine clinical practice conditions in Spain. MethOds: 
Secondary economic analysis based on data from a multicenter, observational and 
prospective cost-of-illness study in patients with chronic PNP refractory to previous 
treatment. Data on resources utilization and pain intensity was collected at baseline 
and 12 weeks after starting a new treatment. Pain intensity was measured using the 
0-100 mm Visual Analogue Scale (VAS) of the Short Form McGill Pain Questionnaire. 
Univariate and multivariate linear regression models were fitted to identify inde-
pendent predictors of costs and health care and non-health care resources utiliza-
tion. Results: A total of 1703 patients were included in the current analysis. Pain 
intensity was an independent predictor of total costs ([Total costs(Euros)] = 35.6 x 
[VAS pain intensity] + 214.5; coefficient of determination [R2]= 0.19, p< 0.001), direct 
costs ([Direct costs(Euros)] = 10.8 x [VAS pain intensity] + 257.7; R2= 0.06, p< 0.001) 
and indirect costs ([Indirect costs(Euros)] = 24.8 x [VAS pain intensity] – 43.4; R2= 0.19, 
p< 0.001) related to chronic PNP in the univariate analysis. Pain intensity remain 
significantly associated with total costs, direct costs and indirect costs after adjust-
ment by other covariates in the multivariate analysis (p< 0.001). The impact of pain 
intensity on health care and non-health care resources utilization accounted for 
such findings. cOnclusiOns: Pain intensity predicts the health care and non-
health care resources utilization, and costs related to chronic PNP. Management of 
patients with drugs associated with a higher reduction of pain intensity will have 
a greater impact on the economic burden of that condition.
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Objectives: Pemphigus and pemphigoid are a rare group of potentially fatal dis-
eases, causing blistering on mucosal and epidermal surfaces. Long-term treatment 
with systemic corticosteroids and immunosuppressive agents such as intravenous 
immunoglobulin (IVIg) are usually required. Rituximab (RTX) is increasingly being 
used for autoimmune bullous dermatoses (AIBD) and has shown to be effective, 
however, in Canada, RTX is not approved for AIBD. Given the potential cost associ-
ated with the use of RTX, there is a need to quantify the issues around accessing 
it for AIBD patients. MethOds: Resources (e.g., treatment, lab costs, procedures, 
access to health care providers) associated with 89 AIBD patients were collected 
and quantified 6 months prior and 6 months post RTX initiation. Costs of adverse 
events secondary to standard treatment (e.g., steroid adverse effects such as dia-
betes, cataracts, osteoporosis etc) and costs of medications used to prevent steroid 
adverse effects (e.g., proton pump inhibitors, bisphosphonates) were not calculated. 
Unit costs (2013 $CAN) were applied to the resources. Overall cohort costs pre and 
post RTX, as well as cost per patient, were calculated. Cost drivers were identi-
fied. Results: The overall cohort cost for 6 months pre-RTX was $3.7million (M), 
and 6 months post was $2.6M (30.3% decrease). IVIg was shown to be the main 
cost driver. 6 months pre-RTX, 157 months of IVIG was used ($3.6M) compared to 
71 months ($1.6M) 6 months post. The cost associated with access to health care 
resources significantly reduced from $46,715 vs. $22,978, and fewer visits to the 
dermatologist were required (377 vs. 256 visits). A decrease was also observed in 
the cost of specialist consultations required ($5,807 vs. $3,234) and other treatment/
medication use ($64,548 vs. $48,045). The cost per patient decreased ($41,497 vs. 
$28,923). cOnclusiOns: RTX is effective in reducing the number of resources and 
costs associated with treatment of AIBD.
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outcomes. Regarding the acceptability threshold in Poland cysteamine therapy 
can be considered a cost-effective technology compared with CaST in patients 
who began treatment before the age of two.
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Objectives: To assess the cost-effectiveness of sugammadex compared with 
neostigmine + glycopyrrolate as a reversal agent for moderate and deep rocu-
ronium or vecuronium-induced neuromuscular blockade (NMB) in the elective 
setting in England and Wales, when extubation occurs at a train-of-four (TOF) ratio 
of 0.9. MethOds: A decision tree comparing the cost-effectiveness of sugamma-
dex versus neostigmine + glycopyrrolate when reversing moderate or deep NMB 
induced by commonly used neuromuscular blocking agents (NMBAs) (atracurium/
rocuronium/vecuronium) was developed. Extubation was modelled to occur at a 
TOF ratio of 0.9, as may happen when using objective NMB monitoring to deter-
mine when to safely extubate. Time to recovery was used to calculate the cost 
of patients recovering in theatre based on both the average cost per minute of 
theatre time, and operating room (OR) staff costs per minute. Effectiveness was 
measured by the number of prolonged paralysis cases prevented by each treat-
ment regimen. Results: Reversal of moderate NMB: when considering average 
cost per minute of theatre time, results show that sugammadex strategies are 
dominant compared with all assessed comparators. When considering OR staff 
cost per minute, results show that rocuronium with sugammadex is dominant 
over all assessed comparators, with the exception of atracurium with neostigmine 
+ glycopyrrolate (ICER< £100). Reversal of deep NMB: when considering either 
costing scenario, results show that sugammadex strategies are dominant over 
all assessed comparators, with the exception of atracurium with neostigmine + 
glycopyrrolate (ICER < £330). cOnclusiOns: In clinical settings where extubation 
occurs at a TOF ratio of 0.9, and time savings may be realized for all OR staff, under 
both moderate and deep NMB scenarios in the elective surgery setting, sugam-
madex is either dominant or shows reasonable levels of cost-effectiveness (with 
low ICERs < £330 when not dominant against neostigmine+ glycopyrrolate), whilst 
also filling an unmet need for deep NMB reversal.
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Objectives: A vaccine is licensed in Europe for the prevention of Herpes Zoster 
(HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years. The objective of 
this study was to assess the cost-effectiveness of a vaccination programme in 
Germany in this population. MethOds: An existing European Markov Model was 
adapted to the German health care setting and cost-effectiveness outcomes were 
assessed from the statutory health insurance (SHI) and from the societal perspec-
tive. The Markov Model compares a HZ vaccination policy for adults aged ≥ 50 
years with a no vaccination policy. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). Model outcomes include cost/HZ case avoided, cost/
PHN case avoided and cost/quality-adjusted life year (QALY) gained. Additionally 
we assessed the number needed to vaccinate (NNV) to avoid one case of HZ or PHN. 
Input data were obtained from German data sources, international and German 
study results as well as published literature. Discounting was done in accordance 
to guidelines from the German Institute for Quality and Efficiency in Health Care 
(IQWiG). Results: Preliminary results of the base-case analysis show incremen-
tal cost-effectiveness and cost-utility ratios (ICER) in amount of € 2,223 per HZ 
case avoided and € 22,923 per QALY gained from a payer perspective. In sensitiv-
ity analyses discount rates, vaccine prices and no hospitalization assumption 
showed a major impact on the results. cOnclusiOns: Our cost-effectiveness 
analysis shows that a HZ vaccination policy for adults aged ≥ 50 years in Germany 
could provide public health and economic effects in the German health care 
system.
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Objectives: An increased risk for fractures has been observed in patients 
treated with opiates, possibly resulting from falls related to central nervous 
system effects, such as dizziness. Observational data suggest that the semisyn-
thetic opioid, buprenorphine, may be associated with a lower fracture risk than 
some other opiates such as tramadol. Our objective was to perform a preliminary 
analysis to explore whether a buprenorphine-class drug has the potential to be 
cost-effective due to a reduced risk for fracture. MethOds: Decision-analytic 
modeling was used to project fracture-related outcomes and costs over 1 year. 
Quality-adjusted life-years (QALYs) and costs (in 2012 pounds sterling) were esti-
mated from a health service perspective. Odds ratios for forearm, hip, and spine 
fractures, by drug, estimated from real-world hospital discharge data (Vestergaard 
et al., 2006), were applied to the risk for fracture in the general population. 
ing ponatinib provided more than double (2.2-fold) the MCyR months at 36% 
higher cost compared to the 2G TKI strategy. The average cost/MCyR month 
with ponatinib was lower than the average cost/MCyR month with 2G TKIs. 
While there are limitations with the methology and assumptions of the model, 
this analysis suggests treatment with ponatinib may provide good value for 
ponatinib-eligible Italian patients.
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Objectives: To estimate the cost-effectiveness of using the capsaicin patch 
QUTENZATM prior to use of more costly neuropathic pain medications for individu-
als with peripheral neuropathic pain (PnP). MethOds: A decision tree and Markov 
model was developed using inputs from a prospective, observational study. This 
study provided estimates of clinical efficacy, health utility and resource use. The 
model considered two treatment strategies: 1. a capsaicin patch followed by pre-
gabalin and then a subsequent last-line therapy, and 2. no exposure to a capsaicin 
patch. A systematic review and meta-analysis were used to estimate the effective-
ness of pregabalin. Response was defined as a ≥ 50% reduction in pain at week-8. 
Patients who responded were assumed to experience pain relief and increase in 
health-related quality of life until the resolution of pain (or death). Non-responders 
were assumed to switch therapy, and individual’s that failed last-line therapy were 
assumed to experience baseline pain (unless resolution of pain or death). Costs 
were based on published sources. The primary outcome was the incremental cost-
effectiveness ratio (ICER). The perspective was the UK National Health Service and 
personal social services. Results: Key parameter estimates derived from the 
observational study were: the probability of response for capsaicin patch (29.5%), 
the mean number of patches per application (1.5), the mean time to retreatment 
(218 days), The baseline EQ-5D score was 0.370; response was associated with an 
increase in EQ-5D utility of 0.353 from baseline. The base-case ICER was £2,292 per 
quality-adjusted life-year (QALY). This varied by time horizon. Probabilistic sensi-
tivity analysis suggested that over a lifetime horizon, a treatment strategy placing 
capsaicin patches before pregabalin had a 99.9% probability of being cost effective 
at a willingness-to-pay threshold of £20,000. cOnclusiOns: The capsaicin patch 
used before pregabalin was a highly cost-effective treatment in the management 
of peripheral neuropathic pain.
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Objectives: To evaluate the cost effectivenss of Thiopentone and Propofol for over 
night induction anesthesia in a tertiary care hospital. MethOds: A prospective 
observational study in which the patients scheduled for general anaesthesia were 
adminsitred EQ5D 5L(Qol question aire) after six hour and 24 hours of administering 
Induction Aneasthesia. Kuppuswamy scale was applied to asses the socioeconomic 
status along with the demographic detials Results: The average of EQ5D5L scores 
for Propofal was 14.2 and for Thiopentone 16.0. The cost of the Propofol brand used 
in hospital were 250INR and 260INR. Thiopentone , only one brand was avialable 
costing 62 INR. The Propofol was the most commonly used induction anesthetic 
and it costs more than 4 times of Thipentone. The patients socioeconomic catego-
rirzation based on Kuppuswmy Scale revealed nearly 50% of patients belonged to 
lower middle class and 35% middle class and rest of the patients to Upper class. 
Incremental cost effectivness ratio for Thiopentone agianst Propofol was found 
to be -110; cOnclusiOns: The Propofol although expensive does not offer any 
advantage over the Thiopentone as for quality of life among patients who under 
went induction anethesia
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Objectives: To perform a cost-effectiveness analysis (CEA) of cysteamine in the 
treatment of infantile cystinosis vs. control group consisting of patients who had 
been given only conservative and symptomatic treatment (CaST). MethOds: 
Markov model was developed in TreeAge Pro 2009. The model evaluated the costs 
and health outcomes of cysteamine treatment at a dose of 1.30 g/m2/day com-
pared with the use of CaST. The model distinguished two populations, depending 
on the time of initiation of the treatment (before the age of two – P1 and after 
the age of two – P2, which implies worse prognosis for the time of occurrence of 
end stage renal disease (ESRD)). The CEA was conducted from both a common 
payer perspective (a patient and a public payer) and a public payer perspective. 
The time horizon of the analysis covered the period from the age of one or four 
(depending on the start of cysteamine therapy) to fifty (currently, the oldest liv-
ing patients with cystinosis reach the fifth decade of life). The main measures 
of the outcomes in the CEA were life-years gained (LYG) and life-years gained to 
the onset of ESRD. Results: From the common payer perspective the cost per 
LYG was PLN 95,337 and PLN 192,272, respectively for the population P1 and P2. 
Cost of LYG to the onset of ESRD was PLN 33,317 and PLN 64,163, respectively for 
populations P1 and P2. The results obtained from the public payer perspective 
did not differ significantly from the results obtained from the common payer 
perspective. cOnclusiOns: Cysteamine treatment of patients with cystinosis vs. 
therapy involving only CaST is more expensive, however produces better health 
